medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 3

<< Back Next >>

Med Int Mex 2022; 38 (3)

Correlation of total proteins, albumin and uric acid as biomarkers of peritonitis associated to peritoneal dialysis in patients with chronic kidney disease stage 5 KDIGO in continuous ambulatory peritoneal dialysis

Soto-García O, Sánchez-Avilés TA, Cruz-Mendoza C, Prestegui-Muñoz DE, Lozada-Pérez CA, López-Islas I, Soto-García G, Madariaga-Cortés B

Language: Spanish
References: 32
Page: 489-496
PDF size: 194.74 Kb.


ABSTRACT

Objective: To determine the correlation between the biomarkers: total proteins, albumin in dialysis fluid, serum albumin and uric acid in patients with peritonitis associated with dialysis in continuous ambulatory peritoneal dialysis modality.
Materials and Methods: Case-control, observational, analytical, cross-sectional, recuenretrospective, retrolective study that included patients with peritonitis associated with peritoneal dialysis, from 2018 to 2020. χ2 and odds ratio (OR) were used, as well as Pearson’s correlation for the variables total proteins, serum albumin, peritoneal albumin and uric acid.
Results: A population of 60 subjects was studied. A decreased total serum protein was observed with a correlation of 0.792, OR 2.5 higher (p = 0.01). A low serum albumin with a correlation of 0.751, OR 1.7 higher (p = 0.025). Low peritoneal albumin has a correlation of 0.751, OR 2 higher (p = 0.021), with uric acid under a correlation of 0.832, OR 4.3 higher (p = 0.019).
Conclusions: It was possible to identify a statistically significant correlation among the biomarkers total proteins, albumin and uric acid with peritonitis associated with dialysis in patients with chronic kidney disease stage 5 KDIGO in continuous ambulatory peritoneal dialysis.


REFERENCES

  1. Méndez-Durán A, Méndez-Bueno JF, Tapia-Yáñez T, Muñoz-Montes A, Aguilar-Sánchez L. Epidemiología de la insuficienciarenal crónica en México. Dial Traspl 2010; 31 (1):7-11. DOI: 10.1016/S1886-2845(10)70004-7.

  2. Levey A, Coresh J, Balk E. National Kidney FoundationPractice Guidelines for Chronic Kidney Disease: Evaluation,classification and stratification. Ann Intern Med 2003;139: 137-147. doi: 10.7326/0003-4819-139-2-200307150-00013.

  3. Guía de Práctica Clínica, Diagnóstico y Tratamiento dela Peritonitis Infecciosa en Diálisis Peritoneal Crónica enAdultos, México: Secretaría de Salud; 2009.

  4. Boudville N, Kemp A, Clayton P, Lim W, et al. Recent peritonitisassociates with mortality among patients treatedwith peritoneal dialysis. J Am Soc Nephrol 2012; 23 (8):1398-1405. doi: 10.1681/ASN.2011121135.

  5. Clinical Practice Guideline for the Evaluation and Managementof Chronic Kidney Disease. KDIGO 2012; 3: 1-150.

  6. Wang Q, Bernardini J, Piraino B, Fried L. Albumin at thestart of peritoneal dialysis predicts the development ofperitonitis. Am J Kidney Dis 2003; 41 (3): 664-669. doi:10.1053/ajkd.2003.50128.

  7. Churchill DN, Taylor DW, Keshaviah PR, Adequacy of dialysisand nutrition in continuous peritoneal dialysis: associationwith clinical outcome. J Am Soc Nephrol 1996; 7: 198-207.doi: 10.1681/ASN.V72198.

  8. Harrison R. Structure and function of xanthine oxidoreductase:where are we now? Free Radic Biol Med 2002; 33:774-97. 10.1016/S0891-5849(02)00956-5.

  9. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, et al.Effects of xanthine oxidase inhibition with allopurinol onendothelial function and peripheral blood flow in hyperuricemicpatients with chronic heart failure: results from 2placebo-controlled studies. Circulation 2002; 105: 2619-24.doi: 10.1161/01.cir.0000017502.58595.ed.

  10. Suliman ME, Johnson RJ, García-López E, Qureshi AR, et al.J-shaped mortality relationship for uric acid in CKD. Am J KidneyDis 2006; 48: 761-71. doi: 10.1053/j.ajkd.2006.08.019.

  11. Fan X, Huang R, Wang J, Ye H, et al. Risk factors for thefirst episode of peritonitis in Southern Chinese continuousambulatory peritoneal dialysis patients. PLoS One 2014; 9:e107485. 10.1371/journal.pone.0107485.

  12. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acidprovides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis.Proc Natl Acad Sci USA 1981; 78: 6858-62. doi: 10.1073/pnas.78.11.6858.

  13. Azechi T, Kanehira D, Kobayashi T, Sudo R, Nishimura A, SatoF, et al. Trichostatin A, an HDAC class I/II inhibitor, promotesPi-induced vascular calcification via up-regulation of theexpression of alkaline phosphatase. J Atheroscler Thromb2013; 20: 538-547. https://doi.org/10.5551/JAT.15826.

  14. Horowitz MC, Bothwell AL, Hesslein DG, Pflugh DL, SchatzDG. B cells and osteoblast and osteoclast development.Immunol Rev 2005; 208: 141-153. doi: 10.1111/j.0105-2896.2005.00328.x.

  15. Chuang SH, Wong HC, Vathsala A, Lee E, How PP. Prevalenceof chronic kidney disease-mineral and bone disorder inincident peritoneal dialysis patients and its associationwith short-term outcomes. Singapore Med J 2016; 57 (11):603-609. doi: 10.11622/smedj.2015195.

  16. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, ConstantiniEG, et al. Mortality risks of peritoneal dialysis and hemodialysis.Am J Kidney Dis 1999; 34: 1065-1074. doi: 10.1016/S0272-6386(99)70012-0.

  17. Suzuki K1, Ishizaki M, Shishido Y. LDH isoenzyme of thedialysate in noninfected PD patients. Adv Perit Dial 1997;13: 174-8.

  18. Vanderlinde RE. Measurement of total lactate dehydrogenaseactivity. Ann Clin Lab Sci 1985; 15 (1): 13-31.

  19. Flanigan MJ, Freeman RM, Lim VS. Cellular responseto peritonitis among peritoneal dialysis patients. Am JKidney Dis 1985; VI (6): 420-424. DOI: 10.1016/s0272-6386(85)80105-0.

  20. Suzuki K, Ishizaki M, Hotta O, Horigome I, Sudo K, KurosawaK, Taguma Y. Usefulness of dialysate fibrin degradationproducts and Lactic dehydrogenase isoenzyme patternsin assessing the clinical course of peritonitis. Perit Dial Int1994; 14: 231-235.

  21. Excell L, Livingston B, McDonald SP. ANZDATA RegistryReport 2010, Adelaide, South Australia, Australia and NewZealand Dialysis and Transplant Registry, 2010.

  22. Fang W, Qian J, Lin A, Rowaie F, Ni Z, Yao Q, Bargman JM,Oreopoulos DG: Comparison of peritoneal dialysis practicepatterns and outcomes between a Canadian and a Chinesecentre. Nephrol Dial Transplant 2008; 23: 4021-4028. doi:10.1093/ndt/gfn372.

  23. Hiramatsu M; Japanese Society for Elderly Patients onPeritoneal Dialysis. How to improve survival in geriatricperitoneal dialysis patients. Perit Dial Int 2007; 27 [Suppl2]: S185-S189.

  24. Fernández-Perpén A, Pérez-Lozano ML, Bajo MA, Albar-VizcainoP, et al. Influence of bicarbonate/low-GDP peritonealdialysis fluid (Bicavera) on in vitro and ex vivo epithelial-tomesenchymaltransition of mesothelial cells. Perit Dial Int2012; 32 (3): 292-3. doi: 10.3747/pdi.2010.00315.

  25. Lai KN, Lam MF, Leung JCK, Chan Y, et al. A study of clinicaland biochemical profile of peritoneal dialysis fluid low inglucose degradation products. Perit Dial Int 2012; 32 (3):280-291. doi: 10.3747/pdi.2010.00176.

  26. Montenegro J. Peritonitis bacteriana. En: Montenegro J,Correa-Rotter R, Riella MC, editores. Tratado de Diálisis Peritoneal.Barcelona: Elsevier, 2009; Capítulo XVI: 283-320.

  27. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, SilbershatzH, Massaro JM, D’Agostino RB, Franzblau C, Wilson PW.Plasma concentration of C-reactive protein and risk ofischemic stroke and transient ischemic attack: The Framinghamstudy. Stroke 2001; 32: 2575-2579. doi: 10.1161/hs1101.098151.

  28. Tuomainen AM, Hyvärinen K, Ehlers PI, Mervaala E, LeinonenM, Saikku P, Kovanen PT, Jauhiainen M, Pussinen PJ.The effect of proatherogenic microbes on macrophage cholesterolhomeostasis in apoEdeficient mice. Microb Pathog2011; 51: 217-224. doi: 10.1016/j.micpath.2011.03.003.

  29. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate andadaptive immunity in the pathogenesis of atherosclerosis.Circ Res 2002; 91: 281-291. doi: 10.1161/01.res.0000029784.15893.10.

  30. Miles R, Hawley CM, McDonald SP, Brown FG, et al. Predictorsand outcomes of fungal peritonitis in peritonealdialysis patients. Kidney Int 2009; 76: 622-8. doi: 10.1038/ki.2009.202.

  31. Portolés J, Janeiro D, Lou-Arnal, López-Sánchez P, OrtegaM, et al: First episodes of peritoneal infection: descriptionand prognostic factors. Nefrologia 2013; 33 (3): 316-24.DOI: 10.3265/Nefrologia.pre2013.Feb.11733

  32. Kam-Tao Li P, Chun-Szeto C, Piraino B, De Arteaga J, FanS, Figueiredo AE, Fish DN, Goffin E, Yong-Lim K, SalzerW, Struijk DG, Teitelbaum I, Johnson DW. ISPD peritonitisrecommendations: 2016 update on prevention andtreatment. Perit Dial Int 2016; 36: 481-508. doi: 10.3747/pdi.2016.00078.




2020     |     www.medigraphic.com